Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up results from CheckMate 649.

被引：0

作者：

Janjigian, Yelena Y.

Moehler, Markus H.

Ajani, Jaffer A.

Shen, Lin

Garrido, Marcelo

Gallardo, Carlos

Wyrwicz, Lucjan

Yamaguchi, Kensei

Cleary, James M.

Elimova, Elena

Bruges, Ricardo Elias

Karamouzis, Michalis

Skoczylas, Tomasz

Bragagnoli, Arinilda

Liu, Tianshu

Tehfe, Mustapha

McCraith, Stephen

Hu, Nan

Zhang, Jennifer

Shitara, Kohei

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY USA

[2] Weill Cornell Med Coll, New York, NY USA

[3] Johannes Gutenberg Univ Mainz, D-55131 Mainz, Germany

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[5] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China

[6] Pontificia Univ Catolica, Santiago, Chile

[7] Fdn Arturo Lopez Perez, Providencia, Chile

[8] Narodowy Inst Onkol, Klin Onkol & Radioterapii, Warsaw, Poland

[9] Canc Inst Hosp JFCR, Tokyo, Japan

[10] Dana Farber Canc Inst, Boston, MA USA

[11] Princess Margaret Canc Ctr, Toronto, ON, Canada

[12] Inst Nacl Cancerol ESE, Bogota, Colombia

[13] Laiko Gen Hosp Athens, Athens, Greece

[14] Med Univ Lublin, Klin Chirurgii Ogolnej Gastroenterol & Nowotworow, Lublin, Poland

[15] Fundacao Pio XII, Barretos, Brazil

[16] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China

[17] Ctr Hosp Univ Montreal, Montreal, PQ, Canada

[18] Bristol Myers Squibb, Princeton, NJ USA

[19] Natl Canc Ctr Hosp East, Kashiwa, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期

关键词：

D O I：

10.1200/JCO.2025.43.4_suppl.398

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：398 / 398

页数：1

共 50 条

[1] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
Shitara, Kohei
Moehler, Markus H.
Ajani, Jaffer A.
Shen, Lin
Garrido, Marcelo
Gallardo, Carlos
Wyrwicz, Lucjan S.
Yamaguchi, Kensei
Cleary, James M.
Elimova, Elena
Maya, Ricardo Elias Bruges
Karamouzis, Michalis
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Tehfe, Mustapha
Feeney, Kynan
Wang, Rui
Nathani, Raheel
Janjigian, Yelena Y.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 306 - 306
[2] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.
Janjigian, Yelena Y.
Shitara, Kohei
Moehler, Markus H.
Garrido, Marcelo
Gallardo, Carlos
Shen, Lin
Yamaguchi, Kensei
Wyrwicz, Lucjan
Skoczylas, Tomasz
Bragagnoli, Arinilda Silva Campos
Liu, Tianshu
Tehfe, Mustapha
Elimova, Elena
Maya, Ricardo Elias Bruges
Cleary, James M.
Karamouzis, Michalis
Soleymani, Samira
Lei, Ming
Amaya-Chanaga, Carlos
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 291 - 291
[3] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649.
Shen, Lin
Bai, Yuxian
Lin, Xiaoyan
Li, Wei
Wang, Jufeng
Zhang, Xiaochun
Pan, Hongming
Bai, Chunmei
Bai, Li
Cheng, Ying
Zhang, Jingdong
Zhong, Haijun
Ba, Yi
Hu, Wenwei
Xu, Rui-Hua
Guo, Weijian
Qin, Shukui
Hu, Nan
McCraith, Stephen
Liu, Tianshu
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 392 - 392
[4] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649
Elimova, Elena
Shitara, Kohei
Moehler, Markus H.
Ajani, Jaffer A.
Shen, Lin
Garrido, Marcelo
Gallardo, Carlos
Wyrwicz, Lucjan S.
Yamaguchi, Kensei
Cleary, James M.
Maya, Ricardo Elias Bruges
Karamouzis, Michalis
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Tehfe, Mustapha
Feeney, Kynan
Wang, Rui
Nathani, Raheel
Janjigian, Yelena Y.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649
Moehler, M.
Janjigian, Y. Y.
Shitara, K.
Garrido, M.
Gallardo, C.
Shen, L.
Yamaguchi, K.
Wyrwicz, L.
Skoczylas, T.
Bragagnoli, A.
Liu, T.
Tehfe, M.
Elimova, E.
Bruges, R.
Cleary, J. M.
Karamouzis, M.
Soleymani, S.
Lei, M.
Amaya, Chanaga C.
Ajani, J. A.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 114 - 115
[6] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649
Janjigian, Yelena Y.
Shitara, Kohei
Moehler, Markus H.
Garrido, Marcelo
Gallardo, Carlos
Shen, Lin
Yamaguchi, Kensei
Wyrwicz, Lucjan
Skoczylas, Tomasz
Bragagnoli, Arinilda Silva Campos
Liu, Tianshu
Tehfe, Mustapha
Elimova, Elena
Maya, Ricardo Elias Bruges
Cleary, James M.
Karamouzis, Michalis
Soleymani, Samira
Lei, Ming
Amaya-Chanaga, Carlos
Ajani, Jaffer A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[7] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 biomarker analyses
Lei, Ming
Janjigian, Yelena Y.
Ajani, Jaffer A.
Moehler, Markus
Wang, Xuya
Shen, Lin
Garrido, Marcelo
Gallardo, Carlos
Yamaguchi, Kensei
Wyrwicz, Lucjan
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Tehfe, Mustapha
Elimova, Elena
Li, Mingshun
Poulart, Valerie
Wang, Yu
Doshi, Parul
Shitara., Kohei
CANCER RESEARCH, 2022, 82 (12)
[8] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate
Moehler, Markus
Janjigian, Yelena Y.
Shitara, Kohei
Garrido, Marcelo
Gallardo, Carlos
Shen, Lin
Yamaguchi, Kensei
Wyrwicz, Lucjan
Skoczylas, Tomasz
Bragagnoli, Arinilda
Liu, Tianshu
Tehfe, Mustapha
Elimova, Elena
Bruges, Ricardo
Cleary, James M.
Karamouzis, Michalis
Soleymani, Samira
Lei, Ming
Chanaga, Carlos Amaya
Ajani, Jaffer A.
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 64 - 64
[9] Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
Moehler, M.
Shitara, K.
Garrido, M.
Salman, P.
Shen, L.
Wyrwicz, L.
Yamaguchi, K.
Skoczylas, T.
Campos Bragagnoli, A.
Liu, T.
Schenker, M.
Yanez, P.
Tehfe, M.
Poulart, V.
Cullen, D.
Lei, M.
Kondo, K.
Li, M.
Ajani, J. A.
Janjigian, Y. Y.
ANNALS OF ONCOLOGY, 2020, 31 : S1191 - S1191
[10] Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study
Janjigian, Y. Y.
Ajani, J. A.
Moehler, M.
Garrido, M.
Gallardo, C.
Shen, L.
Yamaguchi, K.
Wyrwicz, L.
Skoczylas, T.
Bragagnoli, A.
Liu, T.
Tehfe, M.
Elimova, E.
Li, M.
Poulart, V.
Lei, M.
Kondo, K.
Shitara, K.
ANNALS OF ONCOLOGY, 2021, 32 : S1329 - S1330

← 1 2 3 4 5 →